Evolution of Antibody Immunity to SARS-CoV-2
By
Christian Gaebler,
Zijun Wang,
Julio C. C. Lorenzi,
Frauke Muecksch,
Shlomo Finkin,
Minami Tokuyama,
Alice Cho,
Mila Jankovic,
Dennis Schaefer-Babajew,
Thiago Y. Oliveira,
Melissa Cipolla,
Charlotte Viant,
Christopher O. Barnes,
Yaron Bram,
Gaëlle Breton,
Thomas Hägglöf,
Pilar Mendoza,
Arlene Hurley,
Martina Turroja,
Kristie Gordon,
Katrina G Millard,
Victor Ramos,
Fabian Schmidt,
Yiska Weisblum,
Divya Jha,
Michael Tankelevich,
Gustavo Martinez-Delgado,
Jim Yee,
Roshni Patel,
Juan Dizon,
Cecille Unson-O’Brien,
Irina Shimeliovich,
Davide F. Robbiani,
Zhen Zhao,
Anna Gazumyan,
Robert E. Schwartz,
Theodora Hatziioannou,
Pamela J Bjorkman,
Saurabh Mehandru,
Paul D. Bieniasz,
Marina Caskey,
Michel C. Nussenzweig
Posted 05 Nov 2020
bioRxiv DOI: 10.1101/2020.11.03.367391
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected 78 million individuals and is responsible for over 1.7 million deaths to date. Infection is associated with development of variable levels of antibodies with neutralizing activity that can protect against infection in animal models. Antibody levels decrease with time, but the nature and quality of the memory B cells that would be called upon to produce antibodies upon re-infection has not been examined. Here we report on the humoral memory response in a cohort of 87 individuals assessed at 1.3 and 6.2 months after infection. We find that IgM, and IgG anti-SARS-CoV-2 spike protein receptor binding domain (RBD) antibody titers decrease significantly with IgA being less affected. Concurrently, neutralizing activity in plasma decreases by five-fold in pseudotype virus assays. In contrast, the number of RBD-specific memory B cells is unchanged. Memory B cells display clonal turnover after 6.2 months, and the antibodies they express have greater somatic hypermutation, increased potency and resistance to RBD mutations, indicative of continued evolution of the humoral response. Analysis of intestinal biopsies obtained from asymptomatic individuals 4 months after coronavirus disease-2019 (COVID-19) onset, using immunofluorescence, or polymerase chain reaction, revealed persistence of SARS-CoV-2 nucleic acids and immunoreactivity in the small bowel of 7 out of 14 volunteers. We conclude that the memory B cell response to SARS-CoV-2 evolves between 1.3 and 6.2 months after infection in a manner that is consistent with antigen persistence.
Download data
- Downloaded 24,366 times
- Download rankings, all-time:
- Site-wide: 261
- In immunology: 12
- Year to date:
- Site-wide: 147
- Since beginning of last month:
- Site-wide: 147
Altmetric data
Downloads over time
Distribution of downloads per paper, site-wide
PanLingua
News
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!